VolitionRx Limited (NYSEAMERICAN:VNRX) will present preliminary results from its proof of concept clinical studies focused on monitoring disease progression of COVID-19 as part of the "Innovative COVID-19 Diagnostics" session at today's virtual MEDICA LABMED Forum.
The presentation, "Circulating nucleosomes as potential prognostic markers for COVID-19 disease severity" will outline the company's Nu.Q Nucleosomics technology’s ability to identify cell free circulating nucleosomes associated with elevated NETosis — the body's immune response to an infection — in at-risk individuals with COVID-19.
Volition’s initial studies demonstrated that symptomatic COVID-19 patients have elevated circulating nucleosomes. As a result, the company has filed a patent for monitoring disease progression of COVID-19 and other NETosis associated infections.
Data from two independent cohorts of COVID-19 patients with quantitative nucleosome immunoassays showed that nucleosomes were highly elevated in the plasma of patients with severe COVID-19, relative to healthy control subjects.
The highest levels of nucleosomes were found in patients requiring artificial ventilation or extracorporeal oxygenation. Volition believes that nucleosomes could be used to monitor disease progression in COVID-19 patients and potentially other diseases such as influenza and sepsis.
The early identification and triaging of at-risk COVID-19 patients to determine those most likely to deteriorate and require critical care would enable both improved outcomes for patients and a more efficient use of critical care resources for healthcare providers, the company said.
The presentation will be led by Volition founding scientist and business director Mark Eccleston.
"We are very pleased to be invited to present data at the MEDICA LABMED Forum on the work we are doing to use circulating nucleosomes to monitor COVID-19,” Eccleston said in a statement. “As we see the number of cases rise again worldwide, we believe more than ever that the ability to understand disease progression and to manage resources accordingly is an important and still unmet need. We look forward to announcing further data soon."
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel